Skip to content

Improving preconceptional glycaemic regulation using RealTime Continuous Glucose Monitoring in women with type 1 diabetes who have *acceptable but not optimal* HbA1c values: an observational study

Improving preconceptional glycaemic regulation using RealTime Continuous Glucose Monitoring in women with type 1 diabetes who have *acceptable but not optimal* HbA1c values: an observational study - Improving preconceptional glucose regulation in DM1women using RT-CGMS

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35863
Enrollment
10
Registered
2011-07-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Diabetes Mellitus

Interventions

RT-CGMS during 7 consecutive days every other week (in total: 8 of 16 weeks) Results will be used for counseling / treatment adjustments

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - diagnosed with diabetes mellitus 1 at least for one year diagnosis - insulin pump for at least 3 months - reliable performance of SMBG at least 5 times a day for at least 5 days a week - child wish - stable HbA1c 43-53 mmol/mol: the last 2 values +/- 3 mmol/mol - willing to (patient herself) and capable of (as estimated by treating doctor) using RT-CGMS - able to read and speak Dutch - written informed consent - internet access (uploading results sensor)

Exclusion criteria

Exclusion criteria: - co-existent medical problems that would interfere with study participation - use of medication that could influence glycaemic control (for example corticosteroids) in last three months

Design outcomes

Primary

MeasureTime frame
Primary outcome - Absolute reduction in HbA1c

Secondary

MeasureTime frame
Secondary outcomes - Incidence of severe hypoglycaemia - Percentage of women with a fall in HbA1c of >= 5 mmol/mol - number of consultations (by telephone, internet, on the out-patient clinic) - Change in glycaemic variability - Composite end point: reduction of HbA1 >= 5 mmol/mol without an episode of severe hypoglycemia - Frequency of use RT-CGMS - Fear of hypoglycaemia - Quality-of-life - Satisfaction with the device.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)